RxDoctor Payments Data

Ahsan Nazir, MD

Internal Medicine · Hollis, NYNPI 1477543502

Payments from drug & device makers

$3,525in general payments, 2019–2025

Across 31 payments — averaging $113.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$622
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$469
  • Philips North America LLC$339
  • Novo Nordisk$232
  • Amgen$125
  • plus $640 from 6 others

What the payments were for

  • Food & beverage$3,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,525 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$9,230
Medicare patients
22
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate66$49,175
JardianceEmpagliflozin28$24,548
JanumetSitagliptin Phos/Metformin Hcl28$16,414
EliquisApixaban24$14,776
BrilintaTicagrelor13$6,134
Atorvastatin Calcium325$1,986
Metoprolol Succinate92$1,354
Amlodipine Besylate293$1,244
Albuterol Sulfate HfaAlbuterol Sulfate42$1,034
Amlodipine-ValsartanAmlodipine Besylate/Valsartan31$759
Metformin Hcl145$715
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$714
Rosuvastatin Calcium34$677
Losartan Potassium68$647
Ultra-Fine Short Pen NeedlePen Needle, Diabetic12$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$20$65,58994 claims
AstraZenecaBrilinta$1,099$6,13413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hollis

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →